Mineralization-like cascade catalytic nano system based on cholesterol reprogramming as well as preparation method and application of mineralization-like cascade catalytic nano system

Through a mineralization-cascaded catalytic nanosystem based on cholesterol reprogramming, cholesterol oxidase and iron-based metal catalyzed the generation of reactive oxygen species, combined with Avasimibe to regulate cholesterol metabolism, the biotoxicity of traditional nanomaterials and abnormal cholesterol metabolism in tumor microenvironment is solved. The problem has achieved the effect of inhibiting tumor growth and enhancing the anti-tumor immune response.

CN118903393APending Publication Date: 2024-11-08SHENYANG PHARMA UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410929692.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-11
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Traditional nanomaterial synthesis methods may use toxic chemical agents, which lead to biotoxicity and hinder clinical transformation, and abnormal cholesterol metabolism in the tumor microenvironment affects the anti-cancer treatment effect.

Method used

Using a mineralization-cascaded catalytic nanosystem based on cholesterol reprogramming, cholesterol-generating H2O2 is catalyzed by cholesterol oxidase, and the iron-based metal nanozyglass is catalyzed to generate reactive oxygen species, combined with the loaded drug Avasimibe to regulate cholesterol metabolism in tumor cells and T cells. , enhance anti-tumor immune response.

Benefits of technology

It has achieved the inhibition of tumor growth and metastasis, enhanced the anti-tumor immunotherapy effect, provided an efficient anti-tumor nanodelivery system, and the preparation conditions are gentle and the operation is simple.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903393A_ABST
    Figure CN118903393A_ABST
Patent Text Reader

Abstract

The invention discloses a mineralization-like cascade catalytic nano system based on cholesterol reprogramming as well as a preparation method and application thereof, and belongs to the technical field of nano preparations. The preparation method comprises the following steps: adding an atrivamib solution into a cholesterol oxidase solution, stirring, adding a 2-methylimidazole solution, uniformly mixing, standing, adding an iron salt aqueous solution, uniformly mixing, standing, adding a stabilizer, uniformly stirring, performing ultrasonic treatment, dialyzing and centrifuging, thereby obtaining the atrivamib nano system. According to the present invention, the cholesterol content of the tumor site can be efficiently adjusted, the ferroptosis can be cyclically enhanced, the tumor cells can be finally induced to produce immunogenic death, and the strong ferroptosis-mediated immune response can be activated, such that the dendritic cell maturation and the T cell infiltration can be promoted, and the strong anti-tumor immune response can be established by the body; and the compound has excellent anti-tumor effect on tumor recurrence and metastasis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of nano-preparations, and specifically relates to a mineralization-like cascade catalytic nano-system based on cholesterol reprogramming, and a preparation method and application thereof. Background Art

[0002] At present, the incidence and mortality of cancer are increasing every year around the world, gradually becoming the main cause of human death, seriously threatening human life and health. In the emerging field of anti-cancer, chemodynamic therapy (CDT) as an important supplement to traditional cancer therapies (such as surgery, radiotherapy, chemotherapy, etc.) has been considered as a tumor-specific treatment method with minimal harmful side effects. CDT takes advantage of the weak acidity of the tumor microenvironment (TME) and the excess of H2O2, and uses Fenton or Fenton-like reactions to catalyze the conversion of weakly oxidizing H2O2 into strongly oxidizing hydroxyl radicals (·OH), leading to increased intracellular oxidation levels, DNA necrosis, protein inactivation, lipid oxidation, and ultimately inducing cell apoptosis.

[0003] At present, the main method for synthesizing traditional nanomaterials is chemical synthesis. Since chemical synthesis may use toxic chemical reagents, the final synthesized nanomaterials have potential biological toxicity, which hinders further clinical transformation. Biomineralization mainly refers to the process of biological macromolecules and inorganic ions forming organic-inorganic complexes. Bionic mineralized nanomaterials use endogenous biological substances as reactants, so they have good biosafety and solve the problem of long-term toxicity of traditional nanomaterials.

[0004] Tumor cells, as rapidly proliferating cells, require high levels of cholesterol to meet the needs of membrane biosynthesis, migration and other functions. At the same time, the abnormal accumulation of a large number of metabolites in the tumor microenvironment is the main manifestation of abnormal cholesterol metabolism regulation. These cholesterol-derived metabolites play a complex role in suppressing immune responses. Studies have shown that targeting cholesterol metabolism can hinder tumor growth and invasion of various cancers, reshape the immune status, and provide a new option for anti-cancer. Summary of the invention

[0005] In view of this, the purpose of the present application is to provide a mineralization-cascade catalytic nanosystem based on cholesterol reprogramming and its preparation method and application, with mild preparation conditions and simple operation; through cholesterol metabolic reprogramming, ferroptosis, increased oxidative stress, enhanced anti-tumor immune response, etc., the purpose of inhibiting tumor growth and metastasis and enhancing anti-tumor immunotherapy is achieved, and it is an efficient anti-tumor nanodelivery system.

[0006] In order to achieve the above object, the present invention provides the following technical solutions:

[0007] The present invention provides a method for preparing a mineralization-cascade catalytic nanosystem based on cholesterol reprogramming, comprising the following steps:

[0008] (1) Dissolve 2-methylimidazole, iron salt, and cholesterol oxidase in ultrapure water respectively; and dissolve avasimib in an organic solvent;

[0009] (2) Add the avasimib solution to the cholesterol oxidase solution, stir at room temperature for 0.5 to 5 hours, add the dissolved 2-methylimidazole solution, mix well, let stand at room temperature for 5 to 200 minutes, add the iron salt aqueous solution, mix well, let stand at room temperature for 5 to 200 minutes, add the stabilizer, stir well, sonicate, dialyze, and centrifuge to obtain a mineralization-cascade catalytic nanosystem based on cholesterol reprogramming.

[0010] Based on the above technical solution, further, the organic solvent in step (1) is ethanol, and the concentration of the avasimibe solution is 0.5 to 50 mg / mL.

[0011] Based on the above technical solution, further, the iron salt in step (1) includes ferric chloride, ferric sulfate, and ferric nitrate; the concentrations of the 2-methylimidazole, iron salt, and cholesterol oxidase solution are 1-100 mg / mL, 1-100 mg / mL, and 0.5-100 mg / mL, respectively.

[0012] Based on the above technical solution, further, in step (2), the volume ratio of 2-methylimidazole solution, cholesterol oxidase solution and iron salt aqueous solution is 1:1~5:1~5; the volume ratio of avasimibe solution to cholesterol oxidase solution is 1:10~100.

[0013] Based on the above technical solution, further, the stabilizer described in step (2) is one or a combination of two or more of TPGS, PVP, SDS, and HPC, and the concentration of the stabilizer in the solution is 0.1 to 10 mg / mL.

[0014] Based on the above technical solution, further, the molecular weight cutoff of the dialysis bag used for dialysis in step (2) is 3500-4500Da.

[0015] Based on the above technical solution, further, in step (2), the centrifugal speed is 500 to 3000 rpm, and the time is 4 to 120 min.

[0016] On the other hand, the present invention provides a mineralization-cascade catalytic nanosystem based on cholesterol reprogramming prepared by the above-mentioned preparation method.

[0017] Based on the above technical solution, further, the hydrodynamic diameter of the cholesterol-reprogramming-based mineralization-cascade catalytic nanosystem is 100-200 nm, and the Zeta potential is (-30)-(-45).

[0018] On the other hand, the present invention provides the use of the above-mentioned mineralization-like-cascade catalytic nanosystem based on cholesterol reprogramming in the preparation of drugs for treating tumors.

[0019] Based on the above technical solution, further, the tumor includes melanoma.

[0020] Based on the above technical solution, further, the cholesterol reprogramming-based mineralization-cascade catalytic nanosystem is used in combination with an immune checkpoint blocker.

[0021] Based on the above technical solution, further, the immune checkpoint blocker includes αPD-L1.

[0022] The present invention has the following beneficial effects:

[0023] 1. The present invention adopts a biomimetic mineralization method to construct a nanosystem with dual enzyme activity based on cholesterol oxidase (Cholesteroloxidase, COD), wherein COD can catalyze cholesterol and effectively reduce the cholesterol content. The H2O2 generated by the reaction is further catalyzed by the iron-based metal nanozyme in the nanosystem to generate reactive oxygen with cell-killing effect, promoting the occurrence of cellular lipid peroxidation, and coordinating with the immunotherapy induced thereafter to carry out cascade-enhanced multi-modal anti-tumor treatment, thereby inhibiting tumor growth and metastasis and enhancing anti-tumor immunity. In addition, the loaded drug Avasimibe can regulate the cholesterol metabolism of tumor cells and T cells. On the one hand, it can increase the content of free cholesterol in tumor cells, which is further catalyzed by COD to generate hydrogen peroxide, and cyclically enhance ferroptosis. On the other hand, it can increase CD8 + The cholesterol content of T cell membrane induces rapid aggregation of T cell receptors and sustained activation of T cells.

[0024] 2. The preparation conditions of the cholesterol reprogramming-based nanosystem of the present invention are mild and the operation is simple. It achieves the purpose of inhibiting tumor growth and metastasis and enhancing anti-tumor immunotherapy through cholesterol metabolism reprogramming, ferroptosis, increasing oxidative stress, enhancing anti-tumor immune response, etc., and is an efficient anti-tumor nano-delivery system. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to more clearly illustrate the embodiments of the present invention, the drawings related to the embodiments are briefly introduced below.

[0026] Figure 1This is a transmission electron microscope image of AVA-COD@Fe in Example 1;

[0027] Figure 2 Spectrum element analysis of C, N, O, S, and Fe of AVA-COD@Fe in Example 1;

[0028] Figure 3 The particle size and Zeta potential diagram of COD@Fe and AVA-COD@Fe in Example 1;

[0029] Figure 4 This is the electron paramagnetic resonance (ESR) image of ·OH produced by the reaction of COD@Fe with cholesterol detected by 5,5-dimethyl-1-pyrroline-N-oxide (DMPO) in Example 2;

[0030] Figure 5 is the cell survival rate of FeCl3, Fe NPs, COD@Fe, AVA-COD@Fe and mouse melanoma (B16) cells after 24 h of co-incubation in Example 3;

[0031] Figure 6 The cell survival rate after 12 h of incubation of each group of nanosystems with ferroptosis inhibitors in Example 4 (A); the MDA detection results after treatment with different concentrations of AVA-COD@Fe groups (B); the GSH and GSSG detection results after treatment with different concentrations of AVA-COD@Fe groups (C);

[0032] Figure 7 The cholesterol distribution and quantitative analysis of different treatment groups in Example 5 after co-incubation with mouse melanoma (B16) cells for 12 hours (A); the cell membrane integrity and quantitative analysis of each group (B); the movement and migration ability of each group and quantitative analysis (C);

[0033] Figure 8 The figures are the anti-tumor effect diagrams after intratumor injection of different treatment groups in Example 6; (A) is the tumor volume diagram of the unilateral tumor model; (B) is the in situ tumor volume change diagram of the bilateral tumor model; (C) is the distal tumor volume change diagram of the bilateral tumor model;

[0034] Fig. 9 The results of activating immune response after intratumoral injection in different treatment groups in Example 6; (A) DCs, CD4 + T, CD8 + (B) is a statistical diagram of the proportion of T and Tregs cells; (C) is a diagram of the release of cytokines in the bilateral tumor model; (D) is a statistical diagram of the release of cytokines in the bilateral tumor model; (E) is a statistical diagram of the release of cytokines in the bilateral tumor model + T, CD8 + (D) is a graph showing the cytokine release in the bilateral tumor model.

[0035] Fig.10 CD8 after different treatments in Example 7 + Cholesterol profile of T cells. DETAILED DESCRIPTION

[0036] The present invention is described in detail below with reference to the embodiments, but the embodiments of the present invention are not limited thereto. Obviously, the embodiments described below are only partial embodiments of the present invention. For those skilled in the art, other similar embodiments obtained without creative labor all fall within the protection scope of the present invention.

[0037] The reagents, various raw materials, instruments, etc. used in the examples are all conventional products that can be purchased commercially.

[0038] Example 1

[0039] Preparation and characterization of nanodelivery systems

[0040] 1. Preparation of Fe NPs

[0041] 1 mL of 2-methylimidazole aqueous solution (6 mg / mL) was added to 1 mL of ferric chloride aqueous solution (1.5 mg / mL), mixed evenly, allowed to stand at room temperature for 1 h, 20 μL of stabilizer d-α-tocopheryl succinate polyethylene glycol ester (TPGS, 50 mg / mL) was added, stirred evenly, ultrasonicated for 1 min, and dialyzed to obtain Fe NPs;

[0042] 2. Preparation of COD@Fe

[0043] 1 mL of 2-methylimidazole aqueous solution (6 mg / mL) was added to 1 mL of cholesterol oxidase aqueous solution (1.5 mg / mL), mixed evenly, and allowed to stand at room temperature for 30 min. 1 mL of ferric chloride aqueous solution (1.5 mg / mL) was added, mixed evenly, and allowed to stand at room temperature for 1 h. 20 μL of stabilizer d-α-tocopheryl succinate polyethylene glycol ester (TPGS, 50 mg / mL) was added, stirred evenly, ultrasonicated for 1 min, and dialyzed to obtain COD@Fe.

[0044] 3. Preparation of AVA-COD@Fe

[0045] Take 60 μL of avasimib ethanol solution (5 mg / mL) and add it to 1 mL of cholesterol oxidase aqueous solution (1.5 mg / mL), stir at room temperature for 1 h, add 1 mL of 2-methylimidazole aqueous solution (6 mg / mL), mix well, let stand at room temperature for 30 min, add 1 mL of ferric chloride aqueous solution (1.5 mg / mL), mix well, let stand at room temperature for 1 h, add 20 μL of stabilizer d-α succinic acid tocopheryl polyethylene glycol ester (TPGS, 50 mg / mL), stir well, ultrasonicate for 1 min, dialyze, and centrifuge at low speed (2500 rpm, 5 min) to obtain AVA-COD@Fe.

[0046] The morphology of the prepared nanomaterials was observed using a transmission electron microscope (TEM); the elements contained and their distribution in the nanomaterials were analyzed through element mapping; and the particle size and Zeta potential of the nanomaterials were tested.

[0047] TEM image of nanomaterial AVA-COD@Fe Figure 1 As shown, the results show that AVA-COD@Fe has a circular morphology of about 130 nm.

[0048] The element distribution diagram of nanomaterial AVA-COD@Fe is shown in Figure 2 As shown, the results show that the elements contained in AVA-COD@Fe are C, N, O, S, and Fe, and they are evenly distributed.

[0049] The particle size and Zeta potential results of nanomaterials COD@Fe and AVA-COD@Fe are as follows Figure 3 As shown, the results showed that the particle sizes of COD@Fe and AVA-COD@Fe were approximately 127.1nm and 136.8nm, respectively, and the Zeta potentials of COD@Fe and AVA-COD@Fe were approximately -41.3mV and -34.9mV, respectively.

[0050] Example 2

[0051] In vitro detection of OH production from nanomaterial COD@Fe

[0052] COD@Fe (200 μg / mL) was reacted with 2 mM cholesterol for 1 h. DMPO was used as an OH scavenger. The generation of OH was detected by ESR spectroscopy. COD+cholesterol and COD@Fe were used as controls.

[0053] The results are as follows Figure 4As shown, COD@Fe catalyzes cholesterol to generate hydrogen peroxide, and undergoes a Fenton reaction with hydrogen peroxide, with a signal peak of 1:2:2:1, indicating the generation of ·OH. However, no characteristic peaks appeared in the COD+cholesterol and COD@Fe reaction systems, indicating that no ·OH was generated. The final experimental results prove the feasibility of the nanomaterial COD@Fe cascade reaction to produce ·OH.

[0054] Example 3

[0055] Evaluation of the antitumor effect of nanosystems in vitro

[0056] In this example, mouse melanoma cells (B16) were used as the target cells. B16 cells in the logarithmic growth phase were digested and plated at a density of 3×10 4 The cell suspension of 100 μL / mL was inoculated in a 96-well plate and cultured in a 37°C, 5% CO2 incubator for 24 h. Fresh culture medium containing PBS (control), FeCl3, Fe NPs, COD@Fe, and AVA-COD@Fe was added respectively, and culture was continued for 12 h. The culture medium was removed, washed once with PBS, and 100 μL of fresh culture medium containing 10% CCK-8 was added to each well. After incubation at 37°C in the dark for 1 h, the absorbance was detected at 450 nm using a microplate reader.

[0057] The results are as follows Figure 5 As shown, it can be seen that AVA-COD@Fe can significantly inhibit the viability of B16 cells.

[0058] Example 4

[0059] Ferroptosis-related detection

[0060] B16 cells in the logarithmic phase were digested and plated at a density of 3×10 4 Cell suspensions of 100 μg / mL were inoculated in 96-well plates and cultured in a 37°C, 5% CO2 incubator for 24 h. Fresh culture medium containing PBS (control), COD (50 μg / mL), AVA (10 μg / mL), FeNPs (50 μg / mL), COD@Fe (50 μg / mL), AVA-COD@Fe (50 μg / mL) and ferroptosis inhibitors [vitamin E (VE, 100 μM), idebenone (100 μM), deferoxamine (100 μM) or GSH (100 μM)] were added and incubated for 12 h, the culture medium was removed, the plates were washed with PBS, 100 μL of fresh culture medium containing 10% CCK-8 was added to each well, and the plates were incubated at 37°C in the dark for 1 h, and the absorbance was detected at 450 nm using a microplate reader.

[0061] The results are as follows Figure 6As shown in A, ferroptosis inhibitors can effectively alleviate ferroptosis caused by Fe NPs, COD@Fe, and AVA-COD@Fe.

[0062] B16 cells in the logarithmic phase were digested and plated at a density of 1×10 5 The cell suspension of 100 μg / mL was inoculated in a 6-well plate and cultured in a 37°C, 5% CO2 incubator for 24 h. Fresh culture medium containing different concentrations of AVAV-COD@Fe (5, 10, 20, 40, 60 μg / mL) was added and cultured for 12 h. The contents of MDA, GSH and GSSG in the cells were then determined using a lipid oxidation (MDA) detection kit and a GSH and GSSG detection kit according to the operating instructions.

[0063] The results are as follows Figure 6 As shown in BC, the content of MDA increased with the increase of the incubation concentration of AVAV-COD@Fe, indicating that AVA-COD@Fe can induce lipid peroxidation in cells; the cells treated with AVA-COD@Fe showed a concentration-dependent GSH scavenging effect. With the increase of incubation concentration, more GSH was consumed. In addition, the concentration of GSSG in the cells increased, mainly because GSH was oxidized to glutathione disulfide (GSSG).

[0064] Example 5

[0065] Study on the Effect of Nanosystem on Cholesterol Level

[0066] (1) Cholesterol distribution

[0067] B16 cells in the logarithmic phase were digested and plated at a density of 1×10 5 The cell suspension of 100 μg / mL was inoculated in a 12-well plate and cultured in a 37°C, 5% CO2 incubator for 24 hours. Fresh culture medium containing PBS (control), COD (50 μg / mL), AVA (10 μg / mL), FeNPs (50 μg / mL), COD@Fe (50 μg / mL), and AVA-COD@Fe (50 μg / mL) was added respectively and cultured for 12 hours. The culture medium was removed, and the dye Felipin III was added and incubated for 30 minutes. Finally, the fluorescence intensity of each group was observed by fluorescence microscopy. The greater the fluorescence intensity, the higher the cholesterol content of the cells.

[0068] The results are as follows Figure 7As shown in A, compared with the control group, except for the Fe NPs group, the fluorescence intensity in the cells treated with COD and COD@Fe was significantly reduced, indicating that the cholesterol content in the tumor cell membrane and intracellular components decreased. The fluorescence intensity of the cells treated with AVA was enhanced, and the cholesterol level in the cells increased. The fluorescence intensity of the AVA-COD@Fe group was between the COD group and the AVA group and lower than that of the control group, which was mainly due to the bidirectional regulatory effects of COD and AVA on cellular cholesterol levels.

[0069] (2) Cell membrane integrity test

[0070] B16 cells in the logarithmic phase were digested and plated at a density of 1×10 5 The cell suspension of 100 μg / mL was inoculated in a 12-well plate and cultured in a 37°C, 5% CO2 incubator for 24 h. Fresh culture medium containing PBS (control), COD (50 μg / mL), AVA (10 μg / mL), FeNPs (50 μg / mL), COD@Fe (50 μg / mL), and AVA-COD@Fe (50 μg / mL) was added and cultured for 12 h. The culture medium was removed and the cell membrane rupture was detected using a cell membrane integrity detection kit.

[0071] The results are as follows Figure 7 As shown in B, the cell membrane integrity of the Fe NPs, COD@Fe, and AVA-COD@Fe groups was affected after treatment, indicating that reactive oxygen species-induced membrane lipid peroxidation and cholesterol depletion can cause abnormal integrity of tumor cell membranes.

[0072] (3) Cell scratch test

[0073] B16 cells in the logarithmic phase were digested and plated at a density of 1×10 5 A cell suspension of 100 μg / mL was inoculated into a 6-well plate and cultured in a 37°C, 5% CO2 incubator for 24 hours. Until the cell density reaches 90%. Use a 200μL pipette tip to scratch the bottom of the well plate vertically, and gently wash off the scratched cells with PBS. Add fresh culture medium containing PBS (control), COD (50μg / mL), AVA (10μg / mL), FeNPs (50μg / mL), COD@Fe (50μg / mL), and AVA-COD@Fe (50μg / mL), respectively, take photos with an optical microscope at 0 and 24 hours, and calculate the migration rate by measuring the width of migration.

[0074] The results are as follows Figure 7As shown in C, after 24 hours of treatment, the cells in the control group and the Fe NPs group almost completely healed the scratches. Compared with the control group, the COD group, AVA group, COD@Fe and AVA-COD@Fe groups could effectively inhibit the wound healing of B16 cells, and the healing rates were reduced to 36.0%, 26.0%, 25.2% and 25.5%, respectively. The COD, AVA, COD@Fe and AVA-COD@Fe groups all significantly inhibited the migration of B16 cells, indicating that the above-mentioned drug administration groups changed cholesterol reprogramming, thereby inhibiting cell migration.

[0075] Example 6

[0076] Investigating the anti-tumor effect of nanosystems in vivo

[0077] (1) Construction of unilateral tumor model and drug administration regimen

[0078] After digestion and collection of B16 cells in the logarithmic growth phase, the cell suspension was diluted with serum-free medium to adjust the cell density. After shaving the hair on the right back of 6-8 week-old C57 mice with a shaver, 100 μL of the cell suspension was injected subcutaneously. The number of cells inoculated per mouse was 1×10 6 Regularly observe the status of the mice and the subcutaneous tumor formation of the mice. After about a week, when the tumor grows to 100mm 3 At about 14:00 p.m., the mice were randomly divided into 6 groups (control, COD, AVA, Fe NPs, AVA-COD@Fe), with 5 mice in each group. The drugs were administered by intratumoral injection, with a dose of COD 2.5 mg / kg, AVA 0.5 mg / kg, Fe NPs 2.5 mg / kg, COD@Fe 2.5 mg / kg, and AVA-COD@Fe 2.5 mg / kg, once every 4 days, once on days 0, 4, and 8, for a total of 3 times. During the period, the tumor growth was counted, and the tumor was removed after the experiment to detect the infiltration of immune cells. The supernatant of mouse plasma was taken to quantitatively detect the release of cytokines (IL-12p70, IL-6, IFN-γ, TNF-α) by ELISA.

[0079] (2) Construction of bilateral tumor model and drug administration regimen

[0080] After digestion and collection of B16 cells in the logarithmic growth phase, the cell suspension was diluted with serum-free medium to adjust the cell density. After shaving the hair on the right back of 6-8 week-old C57 mice with a shaver, 100 μL of the cell suspension was injected subcutaneously. The number of cells inoculated per mouse was 1×10 6 Regularly observe the status of the mice and the subcutaneous tumor formation of the mice. After about a week, when the tumor grows to 100mm 3When the hair on the left back of 6-8 week-old C57 mice was shaved with a shaver, 100 μL of the cell suspension was injected subcutaneously. The number of cells inoculated per mouse was 1×10 6 The mice were randomly divided into 4 groups (control, αPD-L1, AVA-COD@Fe, αPD-L1+AVA-COD@Fe), with 5 mice in each group. The right tumor was injected in situ, with a dose of αPD-L1 1mg / kg and AVA-COD@Fe 2.5mg / kg. The drug was given once every 4 days, once on days 0, 4 and 8, for a total of 3 times. During the period, the growth of bilateral tumors was counted. After the experiment, the in situ tumors were removed to detect the infiltration of immune cells, and the supernatant of mouse plasma was taken for quantitative detection of the release of cytokines (IL-12p70, IL-6, IFN-γ, TNF-α) by ELISA.

[0081] Tumor volume changes in unilateral tumor model mice Figure 8 As shown in A, compared with the control group, the AVA-COD@Fe group had a significant anti-tumor effect, and the tumor volume was significantly reduced, showing the best anti-tumor effect;

[0082] The results of immune cell infiltration in the tumor of unilateral tumor model mice are as follows Fig. 9 As shown in A, Fe NPs, COD@Fe, and AVA-COD@Fe can enhance the expression of DCs and CD4 + T, CD8 + The proportion of T cells, including DCs and CD4 + T, CD8 + The proportion of T cells increased most significantly, and Tregs cells (CD4 + Foxp3 + The above shows that the AVA-COD@Fe group can promote the infiltration of immune cells into the tumor site and promote the activation of immune cells; the cytokine release is as follows Fig. 9 As shown in B, AVA-COD@Fe administration can significantly promote the release of multiple cytokines including tumor necrosis factor, showing the effect of activating anti-tumor immune response.

[0083] Tumor volume changes in bilateral tumor model mice Figure 8 As shown in BC, in the AVA-COD@Fe group and the αPD-L1+AVA-COD@Fe combination group, the in situ tumor ( Figure 8 B) and distal tumor ( Figure 8 The volume of the in situ tumors was significantly reduced, and the combined group could more significantly inhibit the growth of in situ and distal tumors, showing better anti-tumor effect and anti-metastasis ability; DCs and CD4+ T, CD8 + The proportion of T and Tregs cells is as follows Fig. 9 As shown in C, αPD-L1, AVA-COD@Fe, and αPD-L1+AVA-COD@Fe combined groups were able to enhance the expression of DCs and CD4 + T, CD8 + The ratio of T cells, among which the combined treatment group was the most significant in reducing the effect of Tregs, indicating that the combined group had the strongest infiltration of immune cells into the tumor site after administration; the cytokine release was as follows Fig. 9 As shown in D, both the AVA-COD@Fe group and the combination group can significantly promote the release of multiple cytokines after administration, among which the combination group promotes the release of multiple cytokines more significantly, indicating that the combination group induces a strong anti-tumor immune response.

[0084] Example 7

[0085] Investigating the effect of nanosystem on improving cholesterol distribution in T cell membrane

[0086] (1) Mouse CD8 + Isolation of T cells

[0087] C57BL / 6J OT-Ⅰ mice were anesthetized and euthanized, and the spleen was collected and crushed under sterile conditions to prepare a single-cell suspension. Red blood cells were lysed using ACK lysis buffer at room temperature, and OVA was added. 257-264 Subsequent experiments were performed after 5 days of incubation with peptides and IL-2.

[0088] (2) Cholesterol distribution

[0089] The CD8 + T cells were 1×10 5 The cells were inoculated at a density of 100 cells / mL in a 6-well plate and cultured in a 37°C, 5% CO2 incubator for 24 hours. After the cells were treated with PBS (control), AVA, and AVA-COD@Fe for 12 hours, the dye Felipin III was added and incubated for 30 minutes, and the fluorescence intensity of each group was observed by fluorescence microscopy.

[0090] The results are as follows Fig.10 As shown, compared with the control group, the CD8 + The cholesterol level on the T cell membrane increases, which is conducive to the aggregation of TCR and enhances antigen recognition and response capabilities, thereby increasing tumor infiltration CD8 + The number of T cells.

[0091] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A method for preparing a mineralization-cascade catalytic nanosystem based on cholesterol reprogramming, characterized in that: The following steps are involved: (1) Dissolve 2-methylimidazole, iron salt, and cholesterol oxidase in ultrapure water respectively; and dissolve avasimib in an organic solvent; (2) Add the avasimib solution to the cholesterol oxidase solution, stir at room temperature for 0.5 to 5 hours, add the dissolved 2-methylimidazole solution, mix well, let stand at room temperature for 5 to 200 minutes, add the iron salt aqueous solution, mix well, let stand at room temperature for 5 to 200 minutes, add the stabilizer, stir well, sonicate, dialyze, and centrifuge to obtain a mineralization-cascade catalytic nanosystem based on cholesterol reprogramming.

2. The preparation method according to claim 1, characterized in that: The organic solvent in step (1) is ethanol, the concentration of the avasimibe solution is 0.5-50 mg / mL; the iron salt includes ferric chloride, ferric sulfate, and ferric nitrate; the concentrations of the 2-methylimidazole, iron salt, and cholesterol oxidase solution are 1-100 mg / mL, 1-100 mg / mL, and 0.5-100 mg / mL, respectively.

3. The preparation method according to claim 1, characterized in that: In step (2), the volume ratio of the 2-methylimidazole solution, the cholesterol oxidase solution and the iron salt aqueous solution is 1:1-5:1-5; the volume ratio of the avasimibe solution to the cholesterol oxidase solution is 1:10-100.

4. The preparation method according to claim 1, characterized in that: The stabilizer described in step (2) is one or a combination of two or more of TPGS, PVP, SDS, and HPC, and the concentration of the stabilizer in the solution is 0.1 to 10 mg / mL.

5. The preparation method according to claim 1, characterized in that: The molecular weight cut-off of the dialysis bag used for dialysis in step (2) is 3500-4500Da.

6. The preparation method according to claim 1, characterized in that: The centrifugal speed in step (2) is 500 to 3000 rpm, and the time is 4 to 120 min.

7. A mineralization-cascade catalytic nanosystem based on cholesterol reprogramming obtained by the preparation method according to any one of claims 1 to 6.

8. Use of the cholesterol reprogramming-based mineralization-cascade catalytic nanosystem according to claim 7 in the preparation of drugs for treating tumors.

9. The use according to claim 8, characterized in that: The tumor includes melanoma.

10. The use according to claim 8, characterized in that: The cholesterol reprogramming-based mineralization-cascade catalytic nanosystem is used in combination with an immune checkpoint blocker.